Brought to you by 
Pandion raises $58mm in Series A round
Jan 2018
Executive Summary
Pandion Therapeutics Inc. (bispecific antibodies for inflammatory and autoimmune diseases) raised $58mm through its Series A round. Seed investor Polaris Partners co-led the round, alongside Versant Ventures and Roche Venture Fund. BioInnovation Capital and SR One also took part.
Deal Industry
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pandion raises $58mm in Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice